OptiNose has selected Pharma Tech Industries (PTI) to fill capsules, load cartridges, and package completed delivery systems for NDA batches of its dry powder intranasal sumatriptan, according to Pharma Tech. In November 2012, OptiNose announced positive results from a Phase 3 study of the product, which is delivered using the company’s bi-directional nasal device.
PTI Chairman Tee Noland commented, “It is exciting to work so closely with the team at OptiNose, who have spearheaded the creation of a very promising new drug delivery system, and we are thankful for this opportunity. This project allows PTI to showcase the broad spectrum of capabilities that make us such an attractive option for our customers.”
OptiNose CEO Peter Miller explained, “We chose Pharma Tech Industries as our CMO through a rigorous selection process that evaluated more than half a dozen potential candidates. We are working to bring a groundbreaking delivery system to market, and its commercial development depends upon a partner that can execute with excellence. We believe that Pharma Tech Industries is such a partner.”
According to PTI, the company will also manufacture the devices on a commercial scale if the NDA is approved.
Read the PTI press release.
